Sep 16, 2024
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
Sep 03, 2024
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
Aug 13, 2024
Calliditas Interim Report January to June 2024
Jul 31, 2024
Number of shares and votes in Calliditas Therapeutics
Jul 26, 2024
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
Jul 04, 2024
Launch of Phase 3 clinical trial with Nefecon in Japan
May 28, 2024
Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress
May 23, 2024
Calliditas Q1 report, January - March 2024
May 15, 2024
Notice of annual general meeting of Calliditas Therapeutics AB (publ)
May 15, 2024
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
May 15, 2024
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
May 14, 2024
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
Apr 18, 2024
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Apr 09, 2024
Calliditas Therapeutics to Attend Conferences in April
Mar 06, 2024
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
Mar 01, 2024
Calliditas Therapeutics to Attend Investor Conferences in March
Feb 21, 2024
Calliditas Year-end report, January - December 2023
Feb 14, 2024
Invitation to the presentation of Calliditas´ Year-end report January - December 2023
Feb 13, 2024
Calliditas provides patent update
Jan 08, 2024
Calliditas Therapeutics provides business update ahead of JP Morgan conference